I have a theory about why smart people get burned, and it is not the theory you would expect. It is not that they are lazy, or credulous, or in a hurry. If anything, the people I watch make the worst calls on cognitive peptides are the most careful people I know. They read the mechanism papers. They track their sleep. They have opinions about vitamin D dosing. And that is precisely the trouble. Their competence gets them past the front door, into the actual pharmacology, and once you are standing inside the building admiring the architecture, it is very easy to forget to ask who built it, and whether the elevator has ever been inspected.
Confidence, in other words, is not the opposite of getting fooled. It is often the delivery mechanism.
So before I go any further, the boring part, stated plainly because you would notice if I buried it. None of semax, selank, or dihexa is an FDA-approved cognitive enhancer. What human evidence exists is thin and comes mostly from outside the United States. Dihexa is the shakiest of the three: a foundational paper behind it has drawn a formal notice of concern, a related mechanism paper was retracted, and the clinical drug built on that same mechanism failed in trial. I am not writing this to talk you into any of these compounds. I am writing it to slow down the moment right before you buy one.
The real question isn’t “does it work,” it’s “what happens if you’re wrong”
Here is the reframe I keep coming back to, because it is the one that actually organizes the whole decision. With a compound this thinly studied, asking “does semax work” is almost the wrong question, because nobody, including the researchers, can answer it with confidence yet. The question that actually protects you is different: if this molecule does nothing for you, or does something you didn’t expect, what is standing between you and the fallout? A clinician who evaluated you first? A pharmacy accountable for what’s in the vial? Or nothing at all, just a shipping label and your own optimism?
Run that question through seven specific traps, and you start to see why smart, careful people keep tripping on the same stairs.
Treating three different molecules as one category. Semax is an ACTH-fragment peptide linked to BDNF. Selank descends from an immune peptide and leans toward anxiety relief, not memory. Dihexa is an angiotensin-IV derivative aimed at synapse growth. Saying “I’m going to try a nootropic peptide” is a bit like saying “I’m going to try a pill,” as though the goal doesn’t determine the choice. A clinician who has actually talked to you can match compound to goal. A grid of three vials on a storefront cannot, and won’t try.
Mistaking a real mechanism for a proven benefit. This is the trap built specifically for people who read papers. You learn that semax raises BDNF in a rat hippocampus and some part of your brain quietly finishes the sentence with “so it will make me sharper.” A real biological pathway is not the same thing as a demonstrated benefit in a healthy adult, and this category is stuffed with fascinating pathways and nearly empty of that second thing. An honest source says the mechanism is not the outcome. A sales page sells the mechanism as if it already were.
Not asking where the human evidence actually came from. Most of what exists on semax and selank comes out of Russia, often in Russian-language journals, usually studying sick patients rather than healthy volunteers, and rarely built with the large blinded designs that Western regulators lean on. That doesn’t make the work worthless. It makes it a specific, bounded kind of evidence that does not automatically transfer to you, sitting healthy at your kitchen table. Someone willing to say that out loud is doing you a service. A page that just says “clinically studied” is hiding the fine print.
Taking dihexa’s reputation at face value. Dihexa gets talked about like the serious, elite option, and that reputation is itself the hazard. Its foundational rodent research carries a journal notice of concern, a related mechanism paper has been retracted, and there is no published human efficacy trial behind it. The clinical drug built on the same biological idea failed in its own trial. Anyone selling you dihexa on vibes alone is selling you a reputation resting on a foundation that has, quite literally, been flagged.
Assuming “research use only” means someone checked. This is the trap with the sharpest teeth. “For research use only, not for human consumption” is not a quirky legal footnote, it is the actual basis on which these compounds are sold. It means no clinician looked at your case and said yes. No pharmacy stands behind what’s in the bottle. There is no recall authority if a batch turns out mislabeled or contaminated. A tidy product page and a posted certificate feel like oversight. They are not oversight. They are marketing that has learned to imitate oversight.
Shopping by price per milligram. This math works when a benefit is proven. Here, where the benefit isn’t proven, optimizing on dollars per milligram just quietly steers you toward whoever has stripped out the most accountability, because accountability costs money and the cheapest seller usually skipped it. A provider who prices the whole service, the clinician’s time, the pharmacy, the check-ins, is pricing something different from a vial.
Starting with no plan to ever check back in. The last trap is the quiet one. You take something with early, thin evidence and then never build a way to notice whether it did anything, good or bad. With compounds this poorly mapped, a record over time is the only honest tool you have for telling a real effect from a coincidence, or a side effect from a bad week.
Scoring the two paths against each other
Lay those seven traps next to the two kinds of seller you’ll actually run into, and the pattern isn’t subtle. I weighted honesty about the evidence highest here, because in a category with no proven benefit, a seller who oversells the science is the actual danger, more than any single ingredient.
| Trap the seller helps you dodge | Supervised provider (FormBlends, HealthRX) | Research-chemical seller |
|---|---|---|
| 1. Lumping three molecules into one | Yes, a clinician matches compound to goal | No, just a product grid |
| 2. Mechanism mistaken for proof | Yes, states this plainly | No, sells the mechanism as the pitch |
| 3. Origin of the human evidence | Yes, discloses it is small and foreign | Rarely |
| 4. Dihexa’s flagged foundation | Yes, flags it up front | No |
| 5. The “research use only” gap | Yes, a pharmacy is accountable | No, you are the quality department |
| 6. Shopping on price per milligram | Yes, prices the whole service | No, competes on price alone |
| 7. No follow-up plan | Yes, a way to check in | No, the relationship ends at checkout |
FormBlends comes out on top because the entire structure is built so the right move is the default move, on all seven counts at once. It’s a licensed telehealth provider, meaning the prescribable compounds here pass through an actual physician evaluation, a prescription written when it’s appropriate, and a licensed 503A compounding pharmacy doing the preparing and dispensing, at fair compounded pricing roughly in the range of semax $80 to $200 a month, selank $80 to $180, dihexa $60 to $150, which is worth sitting with, because those are the same molecules a gray-market seller mails you under a “research use only” label. FormBlends is also honest about the ceiling on the evidence rather than dressing these up as proven brain boosters, and it builds in follow-up instead of ending the relationship at checkout. If you want somewhere to log dose alongside changes in focus, mood, or sleep to bring to a check-in, the FormBlends tracker app exists for that logging purpose. It is not a prescription pad and it is not a store.
HealthRX (healthrx.com) lands second, on the same logic: licensed clinical oversight, a required prescription, pharmacy dispensing, and a follow-up structure. Same caveats apply here as everywhere else, compounded products are not FDA-approved finished drugs, and the underlying peptide evidence stays small and mostly foreign no matter who is dispensing it. Choosing between the top two mostly comes down to state licensing and how well the intake fits your situation.
Below that line sit the research-chemical sellers, which by design leave most of the seven traps wide open.
MeriHealth comes in third, a women-focused, physician-supervised telehealth service offering compounded GLP-1 and peptide therapy through licensed compounding pharmacies. What sets it apart is an intake built around female physiology and hormonal context rather than a one-size catalog. The same caveats hold, compounded medications aren’t FDA-approved finished drugs and the peptide evidence base remains thin, but supervised dispensing and follow-up are structurally present, even if the brand is younger and less established than the top two.
WomenRX sits fourth, another women-centered, physician-supervised option for compounded GLP-1 and peptide therapy, dispensed through licensed compounding pharmacies with a stated focus on female health contexts. It ranks just below MeriHealth on track record and depth of follow-up infrastructure, not on any fundamental gap in oversight. The standing caveat applies here too: not FDA-approved, and matching a compound to an individual’s actual goal still depends on an honest conversation about how limited the evidence is.
Biotech Peptides sells a broad catalog of nootropic peptides under research-use labeling, with no clinician, no prescription, and no follow-up. Whether the vial matches the label is a matter of trusting the seller’s word.
Amino Asylum sells these alongside a wider spread of compounds, including SARMs, often competing hard on price, which is the sixth trap wearing a storefront. No oversight, no follow-up.
Core Peptides does post certificates for its peptides, which beats nothing, but it’s a document the seller itself produced, not an FDA-verified guarantee, and the product still arrives research-use-only with nobody on the hook for your particular batch.
Pure Rawz stocks a wide catalog spanning peptides, SARMs, and nootropics under research-use labeling. Breadth, seller-issued paperwork at best, no medical provider anywhere in the chain.
I’m not ranking these on product quality, because nobody outside a lab can verify relative purity from a webpage. The line above separates sellers built to help you avoid the seven traps from sellers built to let you fall into them, and that’s a different, more answerable question than “which vial is purer.”
Where the actual evidence sits, and why the traps are so tempting
None of this would be interesting if the underlying science were dull. It isn’t. Semax has a genuine lab mechanism behind it: a 2006 rat study found a single dose produced “a maximal 1.4-fold increase of BDNF protein levels” in the hippocampus [1]. There’s a real human signal too, in patients rather than healthy volunteers, a 2018 study of 110 stroke patients found semax raised plasma BDNF that “remained high during the whole study period,” tracking with better recovery [2]. Selank carries a small, genuine anxiety signal, a 2008 study of 62 patients reported that “the anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects” [3], which is a nudge, not a transformation. Dihexa is the weak link: its 2013 foundation sits under a Notice of Concern, a related 2014 paper has been retracted [4], one newer mouse study reported it “restored spatial learning and cognitive functions” [6], and the clinical prodrug built on the same mechanism, fosgonimeton, failed its Phase 2/3 Alzheimer’s trial in September 2024 [5]. Read honestly, all of it, and you can see exactly why the traps above are so easy to fall into. There’s just enough real science to make the leap feel reasonable, and not nearly enough to make it safe.
One more legal note, since it underwrites trap five specifically. None of the three compounds is FDA-approved in the United States. Semax and selank are approved in Russia, which carries no regulatory weight here. Dihexa has never been approved anywhere. That leaves the “research use only” label as the actual legal lane these products travel through, not a footnote but the whole basis for the sale. Anyone competing should also check the current WADA prohibited list before touching any of this.
Questions people actually ask me
Do nootropic peptides actually work for cognitive function? Honestly, it depends which peptide you mean and what “work” is supposed to look like. Semax and selank have some genuinely interesting early research behind them, mostly out of Russian clinical settings, hinting at effects on attention and anxiety. But that research stays limited, often small, and rarely gets repeated in Western trials. Calling any of these “proven” right now claims more than the evidence can currently back up.
Are nootropic peptides safe to use? This is where most people stop thinking too soon. “Peptide” describes a shape, not a safety profile, and the compounds under this umbrella vary enormously. Some have relatively mild short-term human data behind them, others have almost none at all. Sourcing changes the risk picture just as much as the molecule does. A peptide from an unverified research-chemical seller carries contamination and dosing risks that a physician-supervised compounding pharmacy like FormBlends exists specifically to guard against.
What are the most studied peptides people use for cognitive performance? Semax, selank, and dihexa are the three names that keep coming up in any serious conversation. Semax has the longest human-adjacent trail, originally studied for stroke recovery, and people stretch that toward healthy-use cognition. Dihexa looks far more potent in animal models but comes with almost no human safety data, a gap people consistently underweight. None of the three is FDA-approved for cognitive enhancement, full stop.
Why does it matter so much where you buy these? Because the supply chain behind “research use” peptides is close to unregulated, and third-party purity testing across that market is inconsistent at best. Independent lab checks have repeatedly turned up dosing errors and contamination in gray-market peptide products. What you believe you’re taking and what’s actually in the vial can be two entirely different things, and that gap, not the molecule itself, is where most of the real risk lives.
References
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006. https://www.sciencedirect.com/science/article/abs/pii/S0006899306022955
- Gusev EI, Martynov MY, Kostenko EV, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018. https://pubmed.ncbi.nlm.nih.gov/29798983/
- Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008.
- Benoist CC, Wright JW, Zhu M, et al. Retraction: The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. Journal of Pharmacology and Experimental Therapeutics.
- Athira Pharma. Topline results from the Phase 2/3 LIFT-AD trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (primary endpoint not met). September 2024.
- Sun M, Chen Z, et al. AngIV-analog dihexa rescues cognitive impairment and recovers memory in the APP/PS1 mouse via the PI3K/AKT signaling pathway. Brain Sciences. 2021.
Written by Paloma Zamora, science reporter. Reading the studies before believing the pitch. Last reviewed May 2026.
Not professional medical advice. Speak with your healthcare provider before making a change.
